Investor Relations

Merrimack is a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of cancer. Merrimack applies its systems biology-based approach to biomedical research, throughout the research and development process. Merrimack currently has six targeted therapeutic oncology candidates in clinical development.

View all »   RSSRecent Releases

Nov 21, 2014
Merrimack Pharmaceuticals Presents on Multiple Programs at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Nov 19, 2014
Merrimack Pharmaceuticals Receives FDA Fast Track Designation for MM-398 in Post-Gemcitabine Metastatic Pancreatic Cancer

Nov 17, 2014
Photo Release -- Merrimack Pharmaceuticals Announces the Addition of Vivian S. Lee, Dean of University of Utah School of Medicine, to Its Board of Directors

Nov 13, 2014
Merrimack Pharmaceuticals to Present Advances on Targeted Cancer Molecules at the 2014 EORTC-NCI-AACR Symposium

View all »Events & Presentations

Dec 10, 2014 at 3:20 PM
Oppenheimer 25th Annual Healthcare Conference

Dec 18, 2014
2014 Analyst Day

Stock Quote (NASDAQ: MACK)

Price:
9.03

Change:
- 0.07

Day High:
9.26

Day Low:
8.95

Volume:
1,996,400

4:00 PM ET on Nov 21, 2014
Delayed ~20 min. By eSignal.

Shareholder Tools